Comparative Pharmacology
Head-to-head clinical analysis: GARAMYCIN versus GENOSYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GARAMYCIN versus GENOSYL.
GARAMYCIN vs GENOSYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis, leading to bacterial cell death.
Genosyl (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine via acetylation to form phenylacetylglutamine. This alternative pathway facilitates waste nitrogen excretion in patients with urea cycle disorders.
Gentamicin 3-5 mg/kg/day IV or IM in 3 divided doses every 8 hours for serious infections; may use once-daily dosing (5 mg/kg IV every 24 hours) for certain indications.
5 mg orally once daily for 14 days, then 2.5 mg orally once daily thereafter.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours in adults with normal renal function; prolonged in renal impairment (up to 40-50 hours in anuria).
Terminal half-life 3.5 hours; clinically relevant for dosing every 6-8 hours in renal impairment.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<2%).
Renal: 85% unchanged; biliary/fecal: 15% as metabolites.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic